奥扎格雷用于冠状动脉支架术后预防急性、亚急性血栓形成  

Ozagrel prevents patients acute thrombosis and subacute thrombosis in patients following primary percutaneous coronary intervention

作　　者：刁繁荣[1] 吕安林[1] 李军杰[1] 苑媛[1] 陈丹[1] 胡小菁[1] 胡艳[1] 

机构地区：[1]第四军医大学西京医院心血管内科,陕西西安710032

出　　处：《心脏杂志》2006年第6期668-671,共4页Chinese Heart Journal

摘　　要：目的评价奥扎格雷在冠状动脉支架置入术（PCI）后预防急性、亚急性血栓形成的有效性和安全性。方法2005年2月～2006年2月不稳定型心绞痛、陈旧性心肌梗死和急性心肌梗死行PCI术患者497例，采用随机双盲方法，分为A、B两组，A组199例，B组298例。B组采用常规抗凝、抗小血板治疗，A组在B组治疗基础上加用奥扎格雷（160mg）静脉滴注，2次／d，连续使用4d。术后观察两组患者临床症状、心电图和实验室指标变化。结果①A组发生急性血栓1例，无亚急性血栓形成，血栓发生率0．5％（1／199）；B组发生急性血栓3例，亚急性血栓8例，血栓发生率3．7％（11／298），两组血栓发生率有统计学意义（P〈0．05）。②A组终点事件发生率为1．0％（2／199），B组终点事件发生率为4．0％（12／298）。两组终点事件比较无统计学意义。③术前、术后1月，两组血细胞、血凝指标变化无显著差异。④A组穿刺局部血肿发生率为2．0％（4／199），B组穿刺局部位血肿发生率为3．0％（9／298），两组均无其它出血等不良反应。结论PCI术后使用奥扎格雷能有效、安全预防急性、亚急性血栓形成。AIM To evaluate the efficacy and safety of ozagrel administration in preventing acute thrombosis and subacute thrombosis in patients who were treated with percutaneous coronary intervention （PCI）. METHODS From February of 2005 to February of 2006, 497 cases with unstable angina, and old and acute myocardial infarction were treated with PCI. All the cases were randomly divided into group A （199 cases） and group B （298 cases）. Group B were treated regularly with anticoagulant and antiplatelet drug. Group A received the same treatment as group, plus a 4-day administration of ozagrel （160mg, iv, twice/d）. The clinical characteristics, changes of electrocardiogram and laboratory indexes were observed. RESULTS （1）One case with acute stent thrombosis was observed and the incidence of thrombosis in group A was 0.5% （1/199）. Eleven cases with stent thrombosis were observed in Group B （3 acute thrombosis and 8 subacute thrombosis） and the incidence of thrombosis in group B was 3.7% （ 11/298 ）. The difference of incidence of thrombosis between group A and group B was significant （ P 〈 0.05）. （2）Two end events happened in group A （2/199） and 12 end events happened in group B （12/ 298 ） . （3）The changes of indexes of hemagglutination and blood cells were not PCI . （4）Four cases with haematoma were observed in group A （4/199） while significant before and after eight patients with haematoma were observed in group B （9/298）. No other hemorrhage phenomenon was observed. CONCLUSION The use of ozagrel after PCI can effectively and safely prevent acute thrombosis and subacute thrombosis.

关 键 词：奥扎格雷 冠状动脉疾病 介入治疗 血栓形成 

分 类 号：R541.4[医药卫生—心血管疾病]